Bicak et al. synthesized an225Ac‐labeled IgG3‐based radioimmunoconjugate of the hexokinase 2–targeting mAb hu11B6 for use in prostate cancer radioimmunotherapy.[59] Their idea was that the increased complement activation and Fcγ receptor binding of the IgG3 scaffold would result in an enhanced anti‐tumor immune response by the active recruitment of effector cells, leading to enhanced radioimmunotherapy. This evidence concerns the gene IGHG3 and prostate carcinoma.